Natco Pharma’s consolidated net profit declined 37 per cent to ₹132 crore in the third quarter ended December 31, 2024, as against ₹212 crore in the same period last year, on account of a decrease in formulation exports.
The total revenue of the Hyderabad-based company also fell to ₹651 crore in the quarter under review, compared to ₹795 crore in the same period last year.
“During the quarter, contribution from the export formulation business was lower. However, the Company expects healthy growth of business in the ensuing quarters,’‘ Natco said in a release.
The Board of Directors has declared a third interim dividend of ₹1.5 per equity share for FY 2024-25.